Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Fluphenazine enanthate [USP:JAN]
RN: 2746-81-8
UNII: QSB34YF0W9
InChIKey: LRWSFOSWNAQHHW-UHFFFAOYSA-N

Classification Codes

  • Antipsychotic
  • Antipsychotic Agents
  • Central Nervous System Agents
  • Central Nervous System Depressants
  • Drug / Therapeutic Agent
  • Human Data
  • Psychotropic Drugs
  • Tranquilizing Agents

Molecular Formula

  • C29-H38-F3-N3-O2-S

Molecular Weight

  • 549.6982
 
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Fluphenazine enanthate
  • Fluphenazine enanthate [USP:JAN]

Synonyms

  • 2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl heptanoate
  • 4-(3-(2-Trifluoromethyl-10-phenothiazinyl)propyl)-1-piperazineethanol enanthate
  • BRN 0598595
  • CCRIS 4033
  • EINECS 220-385-0
  • Eutimox
  • Fluphenazine enantate
  • Fluphenazine enanthate
  • Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
  • Moditen enanthate
  • Moditen-retard
  • Prolixin
  • Prolixin Enanthate
  • SQ 16,114
  • UNII-QSB34YF0W9

Systematic Names

  • Fluphenazine enanthate
  • Fluphenazine O-enantate
  • Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
  • Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- 1-piperazinyl)ethyl ester

Registry Numbers

CAS Registry Number

  • 2746-81-8

FDA UNII

  • QSB34YF0W9

System Generated Number

  • 0002746818

Structure Descriptors

InChI

1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3

InChIKey

LRWSFOSWNAQHHW-UHFFFAOYSA-N

Smiles

CCCCCCC(=O)OCCN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)C(F)(F)F

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human TDLo intramuscular 1633ug/kg (1.633mg/kg) MUSCULOSKELETAL: OTHER CHANGES British Medical Journal. Vol. 2, Pg. 1071, 1966.
human TDLo subcutaneous 357ug/kg (0.357mg/kg) BEHAVIORAL: MUSCLE WEAKNESS American Journal of Psychiatry. Vol. 119, Pg. 779, 1963.
mouse LD50 intramuscular 17200ug/kg (17.2mg/kg)   Drugs in Japan Vol. 6, Pg. 701, 1982.
mouse LD50 intraperitoneal 300mg/kg (300mg/kg)   Drugs in Japan Vol. 6, Pg. 701, 1982.
mouse LD50 intravenous 56mg/kg (56mg/kg)   U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#03337,
mouse LD50 oral 41300ug/kg (41.3mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969.
mouse LD50 subcutaneous 50mg/kg (50mg/kg)   Drugs in Japan Vol. 6, Pg. 701, 1982.
rat LD50 intraperitoneal 230mg/kg (230mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969.
rat LD50 oral 230mg/kg (230mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969.
rat LD50 subcutaneous 475mg/kg (475mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 11, Pg. 1421, 1969.
women TDLo intramuscular 250ug/kg (0.25mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BRAIN AND COVERINGS: CHANGES IN SURFACE EEG

BEHAVIORAL: COMA
Italian Journal of Neurological Sciences. Vol. 1, Pg. 193, 1980.